Our study suggested that FZD7 played an important role in the cross-talk between BMSCs and CML cells, indicating FZD7 could be a potential therapeutic target for CML. This evidence concerns the gene FZD7 and chronic myelogenous leukemia, BCR-ABL1 positive.